ITGAL — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL879320	1.00	20/20
SCHEMBL879361	1.00	20/20
SCHEMBL879369	1.00	20/20
SCHEMBL879397	0.78	20/20
SCHEMBL879362	0.77	20/20
SCHEMBL879396	0.77	20/20
SCHEMBL879360	0.76	20/20
SCHEMBL879319	0.76	20/20
SCHEMBL879334	0.69	20/20
SCHEMBL879338	0.69	20/20
SCHEMBL879367	0.65	20/20
SCHEMBL879401	0.63	20/20
SCHEMBL879391	0.57	20/20
SCHEMBL879351	0.57	20/20
SCHEMBL879343	0.56	20/20
SCHEMBL879340	0.53	20/20
SCHEMBL879387	0.52	20/20
SCHEMBL879390	0.52	20/20
SCHEMBL879341	0.52	20/20
SCHEMBL879404	0.52	20/20

Clinical trials — most relevant to ITGAL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer	PHASE1/PHASE2	COMPLETED
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease	PHASE2	UNKNOWN
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I	PHASE1	WITHDRAWN
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption	PHASE1	COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors	PHASE1	COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	EARLY_PHASE1	UNKNOWN
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis	EARLY_PHASE1	UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors	EARLY_PHASE1	NOT_YET_RECRUITING
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke	EARLY_PHASE1	UNKNOWN
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors	EARLY_PHASE1	RECRUITING
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	EARLY_PHASE1	COMPLETED
177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors	EARLY_PHASE1	RECRUITING
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)	nan	COMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis	nan	COMPLETED
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer	nan	COMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction	nan	COMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis	nan	UNKNOWN
T Lymphocyte Subsets in Ulcerative Colitis	nan	NOT_YET_RECRUITING
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types	nan	COMPLETED
Integrin αvβ6-targeted PET in Malignant Tumors	nan	RECRUITING
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis	nan	COMPLETED
Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study	nan	COMPLETED
CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer	nan	RECRUITING
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer	nan	UNKNOWN
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications	nan	COMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects	nan	UNKNOWN
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ITGAL binder may also engage these)

Protein	Name	Similarity
P24063	—	1.000	P24063 →
P61625	—	1.000	P61625 →
P38570	—	0.998	P38570 →
P05555	—	0.997	P05555 →
Q9QXH4	—	0.996	Q9QXH4 →
Q3V0T4	—	0.995	Q3V0T4 →
Q62470	—	0.995	Q62470 →
ITGAM	Integrin alpha-M	0.993	landscape →
O75578	—	0.993	O75578 →
Q60677	—	0.992	Q60677 →
Q13349	—	0.990	Q13349 →
Q9UKX5	—	0.990	Q9UKX5 →
Q9QYE7	—	0.989	Q9QYE7 →
P11688	—	0.989	P11688 →
Q13797	—	0.987	Q13797 →
P61622	—	0.987	P61622 →
P26006	—	0.987	P26006 →
ITGA2B	Integrin alpha-IIb	0.986	landscape →
ITGA5	Integrin alpha-5	0.986	landscape →
F1MMS9	—	0.986	F1MMS9 →
ITGA2	Integrin alpha-2	0.986	landscape →
Q63258	—	0.985	Q63258 →
Q13683	—	0.985	Q13683 →
E1BFX5	—	0.984	E1BFX5 →
P20702	—	0.984	P20702 →
Q62469	—	0.983	Q62469 →
Q06274	—	0.983	Q06274 →
P53711	—	0.983	P53711 →
Q27977	—	0.983	Q27977 →
Q61738	—	0.982	Q61738 →